Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)
Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
CIAKI is a common iatrogenic. Up to date the suggested treatments for CIAKI are partially
effective and have not been approved by the Food and Drug Administration yet. The lack of
effective nephroprotective drug for CIAKI, emphasizes the need not only for additional new
drugs but also for new strategies that might also clarify CIAKI pathophysiology. To the best
of our knowledge, the potentially beneficial effect of carnitine and PDE5 inhibitors on CIAKI
prevention has not been examined, so far.